Welcome : Guest

INTRAVENOUS IMMUNOGLOBULIN (IVIG) - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million and in Kilograms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -

Bharat Serums and Vaccines Limited
Biotest AG
China Biologic Products, Inc.
CSL Limited
Grifols, S.A.
Hualan Biological Engineering Inc.

Click here to request a full list of companies covered in the report...

Code: MCP-7776
Price: $4950
Companies: 24
Pages: 187
Date: August 2017
Market Data Tables: 72
  Status: * New Report



TABLE OF CONTENTS


  INTRAVENOUS IMMUNOGLOBULIN (IVIG) (Complete Report) Pages : 187   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Immunoglobulins to See Steady Growth.....II-1 1$100
   Table 1: Global Immunoglobulins Market by Segment (2017 & 2022): Percentage Breakdown of Market Value for Intravenous IG, Hyperimmunes and Subcutaneous IG (includes corresponding Graph/Chart).....II-2

Table 2: World Market for Immunoglobulins by Indication (2016): Percentage Breakdown of Market Value for CIDP, PI, Off-Label and Others (includes corresponding Graph/Chart).....II-2
1$350
   Table 3: Leading Players in the Global Immunoglobulin Market (2016E): Percentage Breakdown of Market Value for CSL, Grifols, Octapharma, Shire and Others (includes corresponding Graph/Chart).....II-3
Intravenous Immunoglobulin – A Proliferating Biologic.....II-3
1$350
   Application Areas – A Brief Review.....II-4
Market Outlook.....II-4
1$100
   Growth Drivers and Market Challenges.....II-51$100
   Competitive Scenario.....II-6
Table 4: Leading Players in the Global IVIg Market (2017E): Percentage Breakdown of Revenues for CSL, Grifols, Shire and Others (includes corresponding Graph/Chart).....II-6
Grifols Continues to Consolidate Market Position.....II-6
1$350
   Comparison of Select Drugs and Approved Indications.....II-7
CSL Sees Robust Growth in Immunoglobulin Franchise.....II-7
Shire Continues to Invest Big in Immunoglobulins.....II-7
1$100
   Bivigam Changes Hands Consequent to Unexpected Turn of Events.....II-81$100
   Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of
  Immunoglobulins.....II-9
Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market.....II-9
1$100
   IVIg – The Mainstay of PI Therapy.....II-10
Subcutaneous IG Formulations Gain Therapeutic Foothold.....II-10
1$100
   Table 5: Global Subcutaneous Immunoglobulin Market: 2016-2024 (includes corresponding Graph/Chart).....II-11
Hyperimmune Globulin – Taking IVIg Therapy a Step Ahead.....II-11
Unsuccessful Clinical Trials for Alzheimer’s – A major Setback for IVIg
  Market.....II-11
1$350
   Synthetic Replacements to IVIg Therapy.....II-12
IVIg Therapy – Home-based vs. Outpatient Settings.....II-12
1$100
   Per Capita Consumption Rate Varies Across Countries.....II-13
Table 6: Global Intravenous Immunoglobulin Market (2016): Per Capita Consumption for Select Countries (in Kilograms per Million Inhabitants) (includes corresponding Graph/Chart).....II-13
1$350
   Favorable Reimbursement and High Usage make US the Largest Consumer.....II-14
Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the
  Treatment of SCID.....II-14
Aging Global Population: Major Opportunity Indicator.....II-14
1$100
   Table 7: Global Population Statistics for the 65+ Age Group (2016) (includes corresponding Graph/Chart).....II-151$350
   Table 8: Global Aging Population (in Thousands) by Age Group: 1975, 2000, 2025, and 2050 (includes corresponding Graph/Chart).....II-161$350
   Table 9: Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart).....II-17
Improving Healthcare Expenditure to Foster Growth.....II-17
1$350
   Table 10: Healthcare Spending as % of GDP by Region (2016E) (includes corresponding Graph/Chart).....II-181$350
   Plasma and Plasma Derivatives Continue to Dominate Blood Components Market.....II-19 1$100
   Table 11: World Plasma Products Market by Geographic Region (2016): Percentage Breakdown of Market Value for Asia-Pacific, Europe, North America and Rest of World (includes corresponding Graph/Chart).....II-20

Table 12: World Plasma Products Market by Protein (2016): Percentage Breakdown of Market Value for Albumin, All Factors, IVIG and Others (includes corresponding Graph/Chart).....II-20
1$350
   Table 13: Leading Players in the Global Plasma Market (2016): Percentage Breakdown of Market Value for CSL, Grifols, Octapharma, Shire and Others (includes corresponding Graph/Chart).....II-21

Table 14: Leading Players in Plasma Fractionation by Capacity (2017 & 2022): Percentage Breakdown of Annual Capacity for CSL, Grifols, Kedrion, Octapharma, Shire and Others (includes corresponding Graph/Chart).....II-21
1$350
   Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins.....II-221$100
   Immunoglobulins Overview.....II-23
IVIg and SCIg: A Face-off!.....II-23
Cost of Product and Treatment.....II-23
Side-Effects.....II-23
Frequency of Treatment.....II-23
1$100
   Safety Considerations.....II-24
Patient Response to Treatment Varies.....II-24
Site of Care.....II-24
IVIg Therapy Introduction.....II-24
Intravenous Immunoglobulin.....II-24
1$100
   Mechanism of IVIg Action.....II-25
IVIg Dosage and Treatment Response Time.....II-25
1$100
   Common IVIg Intravenous Dosing Recommendations by Indication.....II-26
Complications and Side Effects of Using IVIg.....II-26
1$100
   Precautions to be Undertaken.....II-27
Intravenous Immunoglobulin – Indications.....II-27
FDA Approved Indications for IVIg.....II-27
1$100
   Off-Label Usage of IVIg.....II-28
Select Off-Label Indications for IVIg.....II-28
1$100
   Applications by Medical Specialty.....II-29
Neurology.....II-29
Hematology.....II-29
Immunology.....II-29
Dermatology.....II-29
Nephrology, Rheumatology, Ophthalmology, and Other Diseases.....II-29
1$100
   LFB Group’s 10% IVIg Gains More Approvals in Europe.....II-30
CSL Acquires Majority Stake in Ruide.....II-30
Baxter Acquires Claris Injectables.....II-30
ADMA Biologics Takes Over BTBU.....II-30
Green Cross Receives FDA Complete Response Letter for IVIG-SN.....II-30
China Biologic Products Completes Acquisition of Guizhou Taibang.....II-30
1$100
   ProMetic Completes Patient Enrolment for Phase III Pivotal IVIG Trial.....II-31
Kroger Combines Axium Pharmacy and Modern HC.....II-31
Shire Acquires Baxalta.....II-31
FDA Accepts BLA for IVIG-SN from Green Cross.....II-31
Kedrion Bags US Commercial Rights to BIVIGAM®.....II-31
China Biologic Products to Commence Clinical Trials on Next-Gen IVIG Products.....II-31
FDA Clears ProMetic’s IND for IVIg.....II-31
1$100
   LFB Obtains Initial Market Authorizations for 10% Liquid IVIg in Europe.....II-32
Baxter Divests its BioScience Division.....II-32
Emergent BioSolutions Acquires Cangene.....II-32
CMS Begins Evaluation of Payment for In-home IVIG Administration.....II-32
1$100
   Bharat Serums and Vaccines Limited (India).....II-33
Biotest AG (Germany).....II-33
China Biologic Products, Inc. (China).....II-33
1$100
   Guizhou Taibang Biological Products Co., Ltd (China).....II-34
CSL Limited (Australia).....II-34
1$100
   Grifols, S.A. (Spain).....II-35
Hualan Biological Engineering Inc. (China).....II-35
1$100
   Kedrion S.p.A. (Italy).....II-36
LFB Group (France).....II-36
Octapharma AG (Switzerland).....II-36
1$100
   Shanghai RAAS Blood Products Co., Ltd. (China).....II-37
Shire plc (Ireland).....II-37
1$100
   Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China).....II-381$100
   Value Analytics.....II-39
Table 15: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-39
1$350
   Table 16: World Historic Review for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-401$350
   Table 17: World 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-411$350
   Volume Analytics.....II-42
Table 18: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-42
1$350
   Table 19: World Historic Review for Intravenous Immunoglobulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-431$350
   Table 20: World 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Volume Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-441$350
   A. Market Analysis.....III-1
Favorable Reimbursement and High Usage Drive Market.....III-1
Approved and Marketed Human Immunoglobulin Products in the US.....III-1
1$75
   Tough Times Ahead for IVIG.....III-21$75
   ProMetic’s IVIg – A Prospective New Drug in the Crowded Market.....III-3
Ageing Demographics: A Key Market Driver.....III-3
1$75
   Table 21: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-4
Intravenous Immunoglobulin Reimbursement Scenario.....III-4
Higher Plasma Center Numbers Key to Secure Raw Material Supply, Costs Remain A
  Bottleneck.....III-4
1$200
   Table 22: Number of Plasma Centers in Operation in the US for Leading Players.....III-5
Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in
  the Treatment of SCID.....III-5
1$200
   US Blood Supply System - A Schematic.....III-6
Strategic Corporate Developments.....III-6
3$225
   B. Market Analytics.....III-9
Value Analytics.....III-9
Table 23: The US Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-9
1$200
   Table 24: The US Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-101$200
   Volume Analytics.....III-11
Table 25: The US Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-11
1$200
   Table 26: The US Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-121$200
   A. Market Analysis.....III-13
Outlook.....III-13
ProMetic – Striving towards Plasma Self Sufficiency.....III-13
Strategic Corporate Development.....III-13
1$75
   B. Market Analytics.....III-14
Value Analytics.....III-14
Table 27: Canadian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-14
1$200
   Table 28: Canadian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-151$200
   Volume Analytics.....III-16
Table 29: Canadian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-16
1$200
   Table 30: Canadian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-171$200
   Market Analysis.....III-18
Value Analytics.....III-18
Table 31: Japanese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-18
1$200
   Table 32: Japanese Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-191$200
   Volume Analytics.....III-20
Table 33: Japanese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-20
1$200
   Table 34: Japanese Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-211$200
   A. Market Analysis.....III-22
Outlook.....III-22
Table 35: European Immunoglobulin (IVIg and SCIg) Consumption (2016): Per Capita Consumption in Kilograms per Million Inhabitants for Select Leading Countries (includes corresponding Graph/Chart).....III-22
Ageing Population Drives Demand.....III-22
1$200
   Table 36: Aged Population in the EU (2016): Population Over 65+ Years as % of Total Population (includes corresponding Graph/Chart).....III-231$200
   Table 37: Life Expectancy at Birth for Select Countries in Europe: 2016 (includes corresponding Graph/Chart).....III-241$200
   Strategic Corporate Developments.....III-251$75
   B. Market Analytics.....III-26
Value Analytics.....III-26
Table 38: European Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-26
1$200
   Table 39: European Historic Review for Intravenous Immunoglobulin by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-271$200
   Table 40: European 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart).....III-281$200
   Volume Analytics.....III-29
Table 41: European Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-29
1$200
   Table 42: European Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-301$200
   A. Market Analysis.....III-31
Outlook.....III-31
Research Initiative in France.....III-31
High-dose Intravenous Immunoglobulin to Offer Respite for Primary Sjögren’s
  Syndrome Patients.....III-31
LFB Group – A Key Player.....III-31
1$75
   B. Market Analytics.....III-32
Table 43: French Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-32
1$200
   Table 44: French Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-331$200
   A. Market Analysis.....III-34
Outlook.....III-34
Biotest AG – A Key Player.....III-34
1$75
   B. Market Analytics.....III-35
Table 45: German Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-35
1$200
   Table 46: German Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-361$200
   A. Market Analysis.....III-37
Outlook.....III-37
Kedrion S.p.A. – A Key Player.....III-37
1$75
   B. Market Analytics.....III-38
Table 47: Italian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-38
1$200
   Table 48: Italian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-391$200
   Market Analysis.....III-40
Table 49: The UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-40
1$200
   Table 50: The UK Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-411$200
   A. Market Analysis.....III-42
Outlook.....III-42
Grifols, S.A. – A Key Player.....III-42
1$75
   B. Market Analytics.....III-43
Table 51: Spanish Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-43
1$200
   Table 52: Spanish Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-441$200
   A. Market Analysis.....III-45
Outlook.....III-45
PRIVIGEN Debuts in Russia.....III-45
Key Players.....III-45
1$75
   B. Market Analytics.....III-46
Table 53: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-46
1$200
   Table 54: Rest of Europe Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-471$200
   Market Analysis.....III-48
Market Analysis.....III-48
1$75
   Value Analytics.....III-49
Table 55: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin by Geographic Region - Australia, China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-49
1$200
   Table 56: Asia-Pacific Historic Review for Intravenous Immunoglobulin by Geographic Region - Australia, China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-501$200
   Table 57: Asia-Pacific 14-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Revenues for Australia, China and Rest of Asia-Pacific Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart).....III-511$200
   Volume Analytics.....III-52
Table 58: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-52
1$200
   Table 59: Asia-Pacific Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-531$200
   A. Market Analysis.....III-54
Overview.....III-54
1$75
   Table 60: Australian IVIg Usage by Main Indications (% of grams used annually) (includes corresponding Graph/Chart).....III-55
Revised Criteria for Clinical Use of IVIg in Australia.....III-55
1$200
   Australian Blood Products Market – An Overview.....III-56
Australian Red Cross Blood Service.....III-56
CSL Limited – A Key Player.....III-56
1$75
   B. Market Analytics.....III-57
Table 61: Australian Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-57
1$200
   Table 62: Australian Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-581$200
   A. Market Analysis.....III-59
Outlook.....III-59
Overview of Chinese Blood Plasma Market.....III-59
1$75
   Table 63: Chinese Plasma Products Market by Product Type (2015): Percentage Breakdown of Value Sales for Albumin, Hyper-immune, IVIg and Others (includes corresponding Graph/Chart).....III-60
IVIG – Strong Opportunities Ahead.....III-60
Domestic Players Rule IVIG Market.....III-60
1$200
   Table 64: Chinese IVIG (Intravenous Immunoglobulin) Products Market by Leading Players (2016): Percentage Breakdown of Volume Sales for China Biologic (CBPO), CNBG Shanghai Institute, Hualan Biological, Shanghai RAAS, and Others (includes corresponding Graph/Chart).....III-61
Strategic Corporate Developments.....III-61
1$200
   Select Key Players.....III-622$150
   B. Market Analytics.....III-64
Table 65: Chinese Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-64
1$200
   Table 66: Chinese Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-651$200
   A. Market Analysis.....III-66
Outlook.....III-66
Plasma Fractionation in Southeast Asia – A Focus on Current and Planned
  Capabilities.....III-66
1$75
   Indonesia – An Overview.....III-67
Bharat Serums And Vaccines Ltd (India) – A Key Player.....III-67
1$75
   B. Market Analytics.....III-68
Table 67: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-68
1$200
   Table 68: Rest of Asia-Pacific Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-691$200
   Market Analysis.....III-70
Value Analytics.....III-70
Table 69: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-70
1$200
   Table 70: Rest of World Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-711$200
   Volume Analytics.....III-72
Table 71: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-72
1$200
   Table 72: Rest of World Historic Review for Intravenous Immunoglobulin Market Analyzed with Annual Consumption Volume in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-731$200
  
Total Companies Profiled: 24 (including Divisions/Subsidiaries - 32)

Region/Country Players

The United States 11 Canada 2 Japan 1 Europe 8 France 1 Germany 1 The United Kingdom 2 Italy 1 Spain 1 Rest of Europe 2 Asia-Pacific (Excluding Japan) 9 Latin America 1
Click here to request a full table of contents and more details on this project.